What should I tell my Ro-affiliated provider before using Wegovy
5.6% said they used Liraglutide, 1.3% said they used Saxenda, and 1.4% said they did not remember the name of the GLP-1 they used
Most ingredients were packed in clear plastic bags grouped by recipe, with each bags outer pocket holding the corresponding recipe carda small but useful organizational detail
This is reflected in the annual investments in fixed assets of CHF 120 million (107 million) in the 2023/24 business year, which will increase to a total of CHF 1,500 million for the next five years
Safety Profiles Side by Side Gastrointestinal Adverse Events | Event | Tirzepatide 15 mg (SURMOUNT-1) | Retatrutide 12 mg (Phase 2) | |---|---|---| | Nausea | 31% | 47% | | Vomiting | 16% | 25% | | Diarrhea | 22% | 17% | | Constipation | 19% | 13% | | Discontinuation due to GI AEs | 4.3% | 16.6% | Discontinuation rates in the retatrutide phase 2 trial were substantially higher than those seen in tirzepatide's phase 3 program, which may reflect a steeper titration schedule, the additional glucagon receptor burden, or the smaller trial population amplifying extreme responders [2][3]
